Cytokinetics (CYTK) Debt to Equity (2016 - 2025)
Historic Debt to Equity for Cytokinetics (CYTK) over the last 13 years, with Q3 2024 value amounting to -$7.59.
- Cytokinetics' Debt to Equity fell 536665.14% to -$7.59 in Q3 2024 from the same period last year, while for Sep 2024 it was -$7.59, marking a year-over-year decrease of 536665.14%. This contributed to the annual value of -$0.18 for FY2023, which is 7047.62% up from last year.
- According to the latest figures from Q3 2024, Cytokinetics' Debt to Equity is -$7.59, which was down 536665.14% from $0.98 recorded in Q2 2024.
- In the past 5 years, Cytokinetics' Debt to Equity registered a high of $2.84 during Q2 2021, and its lowest value of -$7.59 during Q3 2024.
- Over the past 5 years, Cytokinetics' median Debt to Equity value was -$0.14 (recorded in 2023), while the average stood at -$0.42.
- Within the past 5 years, the most significant YoY rise in Cytokinetics' Debt to Equity was 62068.23% (2024), while the steepest drop was 536665.14% (2024).
- Quarter analysis of 5 years shows Cytokinetics' Debt to Equity stood at $0.41 in 2020, then plummeted by 52.34% to $0.19 in 2021, then tumbled by 409.04% to -$0.6 in 2022, then surged by 70.48% to -$0.18 in 2023, then plummeted by 4180.08% to -$7.59 in 2024.
- Its last three reported values are -$7.59 in Q3 2024, $0.98 for Q2 2024, and -$0.17 during Q1 2024.